TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Alzheimer's Disease Research Grants Two $1 Million Centennial Awards Clarksburg, MD - May 1, 2007 /PRNewswire/ --- Alzheimer's Disease Research (ADR) has granted two Centennial Awards of one million dollars each to Dr. Bradley T. Hyman of Massachusetts General Hospital in Boston and Dr. Donald F. Weaver of Dalhousie University in Halifax, Nova Scotia, Canada. The researchers were chosen through a competitive peer review process that began in 2006, marking 100 years since Dr. Alois Alzheimer described this disease. ADR's Centennial Awards will foster innovative, multidisciplinary research, aimed at slowing or reversing the progression of, and ultimately preventing, this devastating brain disorder. feeds.feedburner.com |
YourCity.MD launches Web site nationwide A health care Web site targeted at physicians and consumers went live in about 300 U.S. cities Thursday. feeds.bizjournals.com |
A Win-Win for Isis, Genzyme in Cholesterol Drug Deal Brett Scott submits: Isis Pharmaceuticals (ISIS) came out as the big winner from the JPMorgan Healthcare Conference as the biotech announceda licensing deal with Genzyme (GENZ) for its cholesterol drugmipomersen.Complete Story » seekingalpha.com |
Heparin Contaminant Is Found The FDA found a contaminant in some recalled heparin, but said a connection hasn't been made to allergic reactions seen among some takers of the blood thinner supplied by Baxter. feeds.wsjonline.com |
Will Synta Break A 30-Year Old Record? (Part II) Ohad Hammer submits:For the first part of this article click here. Synta (SNTA) launched a phase I trial in 2004 for the evaluation of elesclomol in combination with paclitaxel in advanced solid tumors. The trial enrolled 35 highly-pretreated patients, who received paclitaxel in combination with escalating doses of elesclomol. There were two partial responses (5.7%), one patient with kaposi’s sarcoma and another patient with ovarian cancer in addition to 15 patients who achieved stable disease. Because this was a combination trial, there was no way of knowing whether elesclomol had a synergistic effect with paclitaxel. Nevertheless, there was evidence that elesclomol can sensitize tumors to chemotherapy, as some of the patients who responded to the treatment had previously progressed during treatment with paclitaxel alone. Another important observation was that elesclomol and paclitaxel can be safely co-administered. Elesclomol then entered three phase II trials in melanoma, non-small-cell lung cancer [NSCLC] and soft tissue sarcoma. Both the NSCLC and the sarcoma trials failed to show a benefit from adding elesclomol to paclitaxel. The melanoma trial, on the other hand, produced a very impressive set of data. Complete Story » seekingalpha.com |